Analysis of aberrant miRNA-mRNA interaction networks in prostate cancer to conjecture its molecular mechanisms.

BACKGROUND MicroRNAs (miRNAs) capable of post-transcriptionally regulating mRNA expression are essential to tumor occurrence and progression. OBJECTIVE This study aims to find negatively regulatory miRNA-mRNA pairs in prostate adenocarcinoma (PRAD). METHODS Combining The Cancer Genome Atlas (TCGA) RNA-Seq data with Gene Expression Omnibus (GEO) mRNA/miRNA expression profiles, differently expressed miRNA/mRNA (DE-miRNAs/DE-mRNAs) were identified. MiRNA-mRNA pairs were screened by miRTarBase and TarBase, databases collecting experimentally confirmed miRNA-mRNA pairs, and verified in 30 paired prostate specimens by real-time reverse transcription polymerase chain reaction (RT-qPCR). The diagnostic values of miRNA-mRNA pairs were measured by receiver operation characteristic (ROC) curve and Decision Curve Analysis (DCA). DAVID-mirPath database and Connectivity Map were employed in GO/KEGG analysis and compounds research. Interactions between miRNA-mRNA pairs and phenotypic features were analyzed with correlation heatmap in hiplot. RESULTS Based on TCGA RNA-Seq data, 22 miRNA and 14 mRNA GEO datasets, 67 (20 down and 47 up) miRNAs and 351 (139 up and 212 down) mRNAs were selected. After screening from 2 databases, 8 miRNA (up)-mRNA (down) and 7 miRNA (down)-mRNA (up) pairs were identified with Pearson's correlation in TCGA. By external validation, miR-221-3p (down)/GALNT3 (up) and miR-20a-5p (up)/FRMD6 (down) were chosen. The model combing 4 signatures possessed better diagnostic value. These two miRNA-mRNA pairs were significantly connected with immune cells fraction and tumor immune microenvironment. CONCLUSIONS The diagnostic model containing 2 negatively regulatory miRNA-mRNA pairs was established to distinguish PRADs from normal controls.

[1]  E. Richardsen,et al.  Overexpression of miR-20a-5p in Tumor Epithelium Is an Independent Negative Prognostic Indicator in Prostate Cancer—A Multi-Institutional Study , 2021, Cancers.

[2]  A. Jemal,et al.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.

[3]  K. D. Sørensen,et al.  FRMD6 has tumor suppressor functions in prostate cancer , 2020, Oncogene.

[4]  A. Vickers,et al.  Screening for Prostate Cancer. , 2020, The Medical clinics of North America.

[5]  B. Schilling,et al.  miR-221-3p Regulates VEGFR2 Expression in High-Risk Prostate Cancer and Represents an Escape Mechanism from Sunitinib In Vitro , 2020, Journal of clinical medicine.

[6]  Yin‐peng Jin,et al.  miR-20a-5p/TGFBR2 Axis Affects Pro-inflammatory Macrophages and Aggravates Liver Fibrosis , 2020, Frontiers in Oncology.

[7]  Jonathan Hall,et al.  miR-221-3p Drives the Shift of M2-Macrophages to a Pro-Inflammatory Function by Suppressing JAK3/STAT3 Activation , 2020, Frontiers in Immunology.

[8]  L. Busund,et al.  Differential expression of the miR-17-92 cluster and miR-17 family in breast cancer according to tumor type; results from the Norwegian Women and Cancer (NOWAC) study , 2019, Journal of Translational Medicine.

[9]  B. Han,et al.  The SOX4/miR-17-92/RB1 Axis Promotes Prostate Cancer Progression , 2019, Neoplasia.

[10]  Isabel R Schlaepfer,et al.  Lipid Metabolism and Endocrine Resistance in Prostate Cancer, and New Opportunities for Therapy , 2019, International journal of molecular sciences.

[11]  A. Hussain,et al.  The evolving role of diet in prostate cancer risk and progression , 2019, Current opinion in oncology.

[12]  Yun Zhang,et al.  Combined Detection of Serum MiR-221-3p and MiR-122-5p Expression in Diagnosis and Prognosis of Gastric Cancer , 2019, Journal of gastric cancer.

[13]  L. Liang,et al.  Cancer-derived exosomal miR-221-3p promotes angiogenesis by targeting THBS2 in cervical squamous cell carcinoma , 2019, Angiogenesis.

[14]  Mengzhu Lu,et al.  Selection and validation of reference genes for quantitative expression analysis of miRNAs and mRNAs in Poplar , 2019, Plant Methods.

[15]  E. Lopez-Lopez,et al.  Systematic Review of the Potential of MicroRNAs in Diffuse Large B Cell Lymphoma , 2019, Cancers.

[16]  Yuan Zhou,et al.  HMDD v3.0: a database for experimentally supported human microRNA–disease associations , 2018, Nucleic Acids Res..

[17]  Yongjun Dang,et al.  Clofoctol and sorafenib inhibit prostate cancer growth via synergistic induction of endoplasmic reticulum stress and UPR pathways , 2018, Cancer management and research.

[18]  Wei Zhu,et al.  Plasma miRNAs in diagnosis and prognosis of pancreatic cancer: A miRNA expression analysis. , 2018, Gene.

[19]  Hanzhang Xu,et al.  Montelukast inhibits hypoxia inducible factor-1α translation in prostate cancer cells , 2018, Cancer biology & therapy.

[20]  Douglas K Owens,et al.  Screening for Prostate Cancer: US Preventive Services Task Force Recommendation Statement , 2018, JAMA.

[21]  Chin-Lee Wu,et al.  Identification of a novel microRNA-mRNA regulatory biomodule in human prostate cancer , 2018, Cell Death & Disease.

[22]  Hua Yu,et al.  JAK/STAT3-Regulated Fatty Acid β-Oxidation Is Critical for Breast Cancer Stem Cell Self-Renewal and Chemoresistance. , 2018, Cell metabolism.

[23]  C. Peng,et al.  Long noncoding RNA NORAD, a novel competing endogenous RNA, enhances the hypoxia-induced epithelial-mesenchymal transition to promote metastasis in pancreatic cancer , 2017, Molecular Cancer.

[24]  P. Wang,et al.  Exploration of the molecular mechanism of prostate cancer based on mRNA and miRNA expression profiles , 2017, OncoTargets and therapy.

[25]  Angela N. Brooks,et al.  A Next Generation Connectivity Map: L1000 Platform and the First 1,000,000 Profiles , 2017, Cell.

[26]  Y. Zhang,et al.  MiR-221-3p targets ARF4 and inhibits the proliferation and migration of epithelial ovarian cancer cells. , 2017, Biochemical and biophysical research communications.

[27]  Wei Tang,et al.  dbDEMC 2.0: updated database of differentially expressed miRNAs in human cancers , 2016, Nucleic Acids Res..

[28]  X. Filella,et al.  Prostate Cancer Detection and Prognosis: From Prostate Specific Antigen (PSA) to Exosomal Biomarkers , 2016, International journal of molecular sciences.

[29]  J. Lozano,et al.  Using gene expression from urine sediment to diagnose prostate cancer: development of a new multiplex mRNA urine test and validation of current biomarkers , 2016, BMC Cancer.

[30]  P. Sanità,et al.  KPT-330, a potent and selective exportin-1 (XPO-1) inhibitor, shows antitumor effects modulating the expression of cyclin D1 and survivin in prostate cancer models , 2015, BMC Cancer.

[31]  Hong Zhang,et al.  MicroRNA Expression Profile Reveals miR-17-92 and miR-143-145 Cluster in Synchronous Colorectal Cancer , 2015, Medicine.

[32]  Fabian Afonso-Grunz,et al.  Principles of miRNA–mRNA interactions: beyond sequence complementarity , 2015, Cellular and Molecular Life Sciences.

[33]  Artemis G. Hatzigeorgiou,et al.  DIANA-miRPath v3.0: deciphering microRNA function with experimental support , 2015, Nucleic Acids Res..

[34]  M. Gessler,et al.  Survival in patients with high-risk prostate cancer is predicted by miR-221, which regulates proliferation, apoptosis, and invasion of prostate cancer cells by inhibiting IRF2 and SOCS3. , 2014, Cancer research.

[35]  G. Getz,et al.  Inferring tumour purity and stromal and immune cell admixture from expression data , 2013, Nature Communications.

[36]  Di Wu,et al.  miRCancer: a microRNA-cancer association database constructed by text mining on literature , 2013, Bioinform..

[37]  F. Sanguedolce,et al.  Combined perianal‐intrarectal (PI) lidocaine‐prilocaine (LP) cream and lidocaine‐ketorolac gel provide better pain relief than combined PI LP cream and periprostatic nerve block during transrectal prostate biopsy , 2012, BJU international.

[38]  W. Filipowicz,et al.  Regulation of mRNA translation and stability by microRNAs. , 2010, Annual review of biochemistry.

[39]  Haiguo Wu,et al.  Targeted high throughput sequencing of a cancer-related exome subset by specific sequence capture with a fully automated microarray platform. , 2010, Genomics.

[40]  Xiaowei Wang,et al.  PrimerBank: a resource of human and mouse PCR primer pairs for gene expression detection and quantification , 2009, Nucleic Acids Res..

[41]  S. Brennecke,et al.  GAPDH, 18S rRNA and YWHAZ are suitable endogenous reference genes for relative gene expression studies in placental tissues from human idiopathic fetal growth restriction. , 2008, Placenta.

[42]  I. Tannock,et al.  Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. , 2004, The New England journal of medicine.

[43]  Thomas D. Schmittgen,et al.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.

[44]  N. Hoosein,et al.  Inhibition by anticonvulsants of prostate-specific antigen and interleukin-6 secretion by human prostate cancer cells. , 2001, Anticancer research.

[45]  Ash A. Alizadeh,et al.  SUPPLEMENTARY NOTE , 1879, Botanical Gazette.

[46]  Maximo J Marin,et al.  Chronic chlorpyrifos exposure does not promote prostate cancer in prostate specific PTEN mutant mice. , 2013, Journal of environmental pathology, toxicology and oncology : official organ of the International Society for Environmental Toxicology and Cancer.